FAQs
What is the new wonder drug for heart failure?
Entresto (sacubitril/valsartan) is often called a "wonder drug" for heart failure because it significantly reduces hospitalizations and cardiovascular deaths in people with reduced ejection fraction (HFrEF)[1][4][16].
How does Entresto work for heart failure?
Entresto combines two active ingredients: sacubitril, which inhibits neprilysin to boost beneficial peptides that relax blood vessels and remove sodium, and valsartan, which blocks angiotensin II to relax blood vessels and lower blood pressure[1][2][5].
What newer medications are available for heart failure besides Entresto?
Recent additions include Farxiga (dapagliflozin) and Jardiance (empagliflozin), SGL-2 inhibitors also shown to reduce hospitalizations; vericiguat, a guanylate cyclase stimulator; and omecamtiv mecarbil, a myosin activator that strengthens heart muscle contraction.
How do the new heart failure drugs compare in effectiveness and cost?
Entresto leads in mortality reduction (about 20% vs placebo), with Farxiga at about 14%, vericiguat at 9%, and omecamtiv mecarbil at 13%. Costs vary, with Entresto around $4,200/year and new agents ranging higher.
When should I talk to my doctor about these new heart failure medications?
Discuss these options if you have HFrEF (LVEF ≤40%), stable blood pressure and kidney function, and are seeking to lower your risk of hospitalization or death. Always review your current medications, labs, and any side effects with your cardiologist.
